Current diagnosis and therapy for head and neck malignancies, An Issue of Surgical Oncology Clinics
(The Clinics: Surgery)
Nicholas J. Petrelli, MD (Consulting Editor) / Wesley L. Hicks, Jr, MD (Guest Editor)
(The Clinics: Surgery)
Nicholas J. Petrelli, MD (Consulting Editor) / Wesley L. Hicks, Jr, MD (Guest Editor)
Surgical Oncology Clinics
Surg Oncol Clin
Published by Elsevier Science.
ISSN: 1055-3207.
Approximately 1,334,100 new cancer cases were diagnosed in 2003. Since 1990, over 17 million new cancer cases have been diagnosed. According to the American Cancer Society, these new cancer cases do not include carcinoma in situ of any site except urinary bladder and do not include basal and squamous skin cancers. In 2003, approximately 556,500 Americans died of cancer, which is equivalent to more than 1500 people a day.
Cancers of the oral cavity and pharynx were diagnosed in an estimated 27,700 new cases in 2003. These incidence rates are more than twice as high in men as in women and are greatest in men who are over age 50. Nevertheless, incidence rates for cancers of the oral cavity and pharynx continued to decline in the 1990s in both African American and white males and females. There were an estimated 7200 deaths in 2003 from oral cavity and pharyngeal cancer. The known risk factors for these cancers are cigarettes, cigars, pipe smoking, and the use of smokeless tobacco. Excessive consumption of alcohol is also a risk factor.
In this issue of the Surgical Oncology Clinics of North America, under the direction of Wesley Hicks, Jr., DDS, MD, an outstanding array of authors has been assembled to discuss many clinical and scientific issues regarding cancers of the head and neck. Dr. Hicks is a member of the Department of Head and Neck Surgery at the Roswell Park Cancer Institute in Buffalo, New York, and an Associate Professor of Surgery at the State University of New York at Buffalo.
The article by Wiseman, Stoler, and Anderson on the role of genomic instability in the pathogenesis of squamous cell carcinoma of the head and neck is especially interesting. These researchers are from the Departments of Surgical Oncology, Experimental Pathology, and Cancer Genetics, respectively. Cancer predisposition genes and the genetic heterogeneity of head and neck tumors are discussed in detail.
On the clinical side, the article by Osborne and Brown from the Division of Otolaryngology/Head and Neck Surgery at the University of CaliforniaLos Angeles Medical Center deals with carcinoma of the oral pharynx with an analysis of subsite treatment heterogeneity. This article provides a clear discussion of the clinical treatment modalities in relationship to histopathologic characteristics.
As I have stated in previous forewords for the Surgical Oncology Clinics of North America, this issue is a must-read for trainees in the three major disciplines of surgery, radiation oncology, and medical oncology. Trainees in pathology and radiology should also make this issue a part of their educational matriculation.
I congratulate Dr. Hicks and his colleagues on an outstanding issue of the Surgical Oncology Clinics of North America.
Nicholas J. Petrelli, MD Consulting Editor Squamous cell carcinoma is the most common histologic malignancy of the head and neck region. Despite this monotonous pathologic presentation, there are a plethora of treatment options and clinical outcomes based on both the site and stage of the primary tumor. The recent movement to combined modality therapy has been driven by the clinical need to improve disease-free survival while minimizing functional and cosmetic morbidity. Here much more work can and should be done. Advancement in treatment and survival in head and neck surgery, in our opinion, requires further translational research efforts melding clinical expertise with bench scientific discovery.
Oncologic head and neck surgery is one of the most clinically challenging and complex areas of surgical oncology. This issue of the Surgical Oncology Clinics of North America presents what we believe is a rational organ-specific approach to malignancies of this region. This issue is not intended to be an exhaustive explanation regarding the armamentarium or clinical paradigms for the treatment of head and neck cancer. We anticipate, however, that it will serve as a solid foundation for those who wish to pursue a personal clinical interest in head and neck surgical oncology.
We anticipate that this issue will give readers a general overview of head and neck cancer and the common surgical/medical approaches to this disease. Each article is a self-contained clinical caveat with a complete explanation of how specific subsites within the head and neck region can be evaluated and treated. After reviewing the articles in aggregate, my belief was affirmed that an understanding of the clinical nuances pertinent to each head and neck subsite must be mastered to obtain effective and improved clinical outcomes.
I wish to express my sincere gratitude and thanks to the contributing authors, whose diligent and exacting work made this issue possible.
Wesley L. Hicks, Jr, MD Guest Editor
http://www.book4doc.com/79740
Surg Oncol Clin
Published by Elsevier Science.
ISSN: 1055-3207.
Approximately 1,334,100 new cancer cases were diagnosed in 2003. Since 1990, over 17 million new cancer cases have been diagnosed. According to the American Cancer Society, these new cancer cases do not include carcinoma in situ of any site except urinary bladder and do not include basal and squamous skin cancers. In 2003, approximately 556,500 Americans died of cancer, which is equivalent to more than 1500 people a day.
Cancers of the oral cavity and pharynx were diagnosed in an estimated 27,700 new cases in 2003. These incidence rates are more than twice as high in men as in women and are greatest in men who are over age 50. Nevertheless, incidence rates for cancers of the oral cavity and pharynx continued to decline in the 1990s in both African American and white males and females. There were an estimated 7200 deaths in 2003 from oral cavity and pharyngeal cancer. The known risk factors for these cancers are cigarettes, cigars, pipe smoking, and the use of smokeless tobacco. Excessive consumption of alcohol is also a risk factor.
In this issue of the Surgical Oncology Clinics of North America, under the direction of Wesley Hicks, Jr., DDS, MD, an outstanding array of authors has been assembled to discuss many clinical and scientific issues regarding cancers of the head and neck. Dr. Hicks is a member of the Department of Head and Neck Surgery at the Roswell Park Cancer Institute in Buffalo, New York, and an Associate Professor of Surgery at the State University of New York at Buffalo.
The article by Wiseman, Stoler, and Anderson on the role of genomic instability in the pathogenesis of squamous cell carcinoma of the head and neck is especially interesting. These researchers are from the Departments of Surgical Oncology, Experimental Pathology, and Cancer Genetics, respectively. Cancer predisposition genes and the genetic heterogeneity of head and neck tumors are discussed in detail.
On the clinical side, the article by Osborne and Brown from the Division of Otolaryngology/Head and Neck Surgery at the University of CaliforniaLos Angeles Medical Center deals with carcinoma of the oral pharynx with an analysis of subsite treatment heterogeneity. This article provides a clear discussion of the clinical treatment modalities in relationship to histopathologic characteristics.
As I have stated in previous forewords for the Surgical Oncology Clinics of North America, this issue is a must-read for trainees in the three major disciplines of surgery, radiation oncology, and medical oncology. Trainees in pathology and radiology should also make this issue a part of their educational matriculation.
I congratulate Dr. Hicks and his colleagues on an outstanding issue of the Surgical Oncology Clinics of North America.
Nicholas J. Petrelli, MD Consulting Editor Squamous cell carcinoma is the most common histologic malignancy of the head and neck region. Despite this monotonous pathologic presentation, there are a plethora of treatment options and clinical outcomes based on both the site and stage of the primary tumor. The recent movement to combined modality therapy has been driven by the clinical need to improve disease-free survival while minimizing functional and cosmetic morbidity. Here much more work can and should be done. Advancement in treatment and survival in head and neck surgery, in our opinion, requires further translational research efforts melding clinical expertise with bench scientific discovery.
Oncologic head and neck surgery is one of the most clinically challenging and complex areas of surgical oncology. This issue of the Surgical Oncology Clinics of North America presents what we believe is a rational organ-specific approach to malignancies of this region. This issue is not intended to be an exhaustive explanation regarding the armamentarium or clinical paradigms for the treatment of head and neck cancer. We anticipate, however, that it will serve as a solid foundation for those who wish to pursue a personal clinical interest in head and neck surgical oncology.
We anticipate that this issue will give readers a general overview of head and neck cancer and the common surgical/medical approaches to this disease. Each article is a self-contained clinical caveat with a complete explanation of how specific subsites within the head and neck region can be evaluated and treated. After reviewing the articles in aggregate, my belief was affirmed that an understanding of the clinical nuances pertinent to each head and neck subsite must be mastered to obtain effective and improved clinical outcomes.
I wish to express my sincere gratitude and thanks to the contributing authors, whose diligent and exacting work made this issue possible.
Wesley L. Hicks, Jr, MD Guest Editor
http://www.book4doc.com/79740
No comments:
Post a Comment